PUBLISHER: MarketsandMarkets | PRODUCT CODE: 1715158

PUBLISHER: MarketsandMarkets | PRODUCT CODE: 1715158

Humanized Mouse and Rat Model Market by Type (Genetic Models, Cell-based Models, Rat Models), Application (Oncology, Immunology, Neuroscience, Toxicology, Infectious Diseases), End User (Pharma, Biotech), and Region - Global Forecast to 2030

PUBLISHED: April 22, 2025

PAGES: 255 Pages

DELIVERY TIME: 1-2 business days

SELECT AN OPTION

The global humanized mouse and rat model market is anticipated to reach USD 409.8 million in 2030 from USD 276.2 million in 2025, with a significant CAGR of 8.2%. The market is growing strongly at a high CAGR due to rising R&D investments of pharmaceutical and biopharmaceutical firms. As the pipeline of R&D expands, the requirement for outsourcing analytical testing is set to rise, in addition to the research initiatives on rare diseases and orphan drugs. Furthermore, the high costs of in-house drug development have also contributed to this trend. Industry players will likely witness healthy growth opportunities due to technological advancements, new drug discovery techniques, patent expirations, and rising demand for specialized testing services among end users.

Scope of the Report
Years Considered for the Study	2024-2030
Base Year	2024
Forecast Period	2024-2030
Units Considered	Value (USD million)
Segments	Type, Application, and End User
Regions covered	North America, Europe, Asia Pacific, Latin America, Middle East, and Africa

"Humanized mouse model segment dominated the type segment in 2024"

Based on type, the humanized mouse and rat model market has been segmented into humanized mouse models and humanized rat models. In 2024, humanized mouse models will have garnered the highest share in terms of revenue in the market. This segment is also expected to grow with the fastest CAGR through the forecast period. An increase in demand for cell-based humanized mouse models has contributed to the segment's growth. These models are utilized in various applications, including the analysis of the safety and effectiveness of potential new drugs and in long-term studies in immuno-oncology, infectious diseases, and graft-versus-host disease.

"The immunology & infectious diseases segment accounted for the second largest share of the market in 2024"

The humanized mouse and rat model market is segmented based on application into oncology, immunology & infectious diseases, neuroscience, hematopoiesis, toxicology, and other applications. The immunology & infectious diseases segment is the second largest segment in the market in terms of revenue. Mouse models are used in immunology and inflammation studies as they help assess the physiological relevance of an experimental finding. Mouse models allow suitable alterations in the mouse genome at random or in specific regions, enabling a detailed study of immunological processes.

"Pharmaceutical & Biotechnology Companies will likely record the highest CAGR during the forecast period"

Based on the end users, the market is segmented into pharmaceutical & biotechnology companies, CROs & CDMOs, and academic & research institutes. Pharmaceutical & biotechnology companies dominated the segment in 2024. The largest share of pharmaceutical and biotechnology companies in the humanized mouse and rat model market is due to the rising expenditure for innovative drug development and the growing preference for personalized medicine. However, the CROs & CDMOs segment is expected to register the highest growth during the forecast period due to the increasing number of pharmaceutical & biotechnology companies outsourcing preclinical studies and research activities for drug development to this end user segment.

"US to record the highest CAGR during the forecast period"

The market is segmented by region into North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. North America dominated the humanized mouse and rat model market in 2024 and is estimated to continue dominating during the forecast period. The US leads the North American market, driven by the presence of key players. The large share of the market is primarily driven by the rising funding for life sciences research and growing research on mAbs and biosimilars. The growing incidence of cancer is also expected to support market growth.

In-depth interviews were conducted with chief executive officers (CEOs), directors, and other executives from various key organizations operating in the humanized mouse and rat model market.

The primary interviews conducted for this report can be categorized as follows:

By Company Type: Tier 1 - 55%, Tier 2 - 25%, and Tier 3 - 20%
By Designation: C-level Executives - 45%, Directors - 30%, and Others - 25%
By Region: North America - 45%, Europe - 30%, Asia Pacific - 20%, Latin America - 3% and Middle East & Africa - 2%

Charles River Laboratories (US), The Jackson Laboratory (JAX) (US), Taconic Biosciences, Inc. (US), JSR Corporation (US) (Crown Biosciences), Champions Oncology, Inc. (US), CLEA Japan Inc. (Japan), genOway (France), Inotiv (US), Janvier Labs (France), Altogen Labs (US), Vitalstar Biotechnology (China), Ingenious Targeting Laboratory (US), Reaction Biology (US), Harbour BioMed (Netherlands), Oncodesign Services (France), Pharmatest Services (Finland), Ozgene Pty Ltd. (Australia), TransCure bioServices (France), Cyagen Biosciences (US), Aragen Life Sciences Ltd. (India), GemPharmatech (China), and Biocytogen (US) are some of the key players in the humanized mouse and rat model market.

Research Coverage:

Humanized mouse and rat model market report is segmented based on type {[(humanized mouse models {genetic humanized mouse models and cell-based humanized mouse models (CD34 humanized mouse models, PBMC humanized mouse models, and BLT humanized mouse models)]} and humanized rat models), application (oncology, immunology and infectious diseases, neuroscience, hematopoiesis, toxicology, and other applications, end user (pharmaceutical & biotechnology companies, CROs & CDMOs, and academic & research institutes), and region (North America, Europe, Asia Pacific, Latin America, and the Middle East, Africa).

The report's scope covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the humanized mouse and rat model market. A comprehensive analysis of the key players in the industry has been conducted to offer insights into their business overviews, products, key strategies, collaborations, partnerships, and agreements. This includes information about recent product launches, collaborations, acquisitions, and humanized mouse and rat model market developments.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing the closest approximations of the revenue numbers for the humanized mouse and rat model and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

Analysis of key drivers (rising use of humanized models in drug discovery research, emerging preclinical applications of humanized mouse models, government-funded initiatives for cancer research, and increasing R&D activities in the pharmaceutical & biotechnology industry), restraints (introduction of FDA Modernization Act 2.0/3.0, stringent regulatory compliance for ethical use of animal models), opportunities (growing preference for humanized PDX models, emergence of CRISPR in biomedical research), and challenges (alternatives for animal testing, limitations of humanized mouse models) influencing market growth.
Product Development/Innovation: Detailed insights on upcoming technologies in humanized mouse and rat models, research and development activities, and new product launches in the humanized mouse and rat model market.
Market Development: Comprehensive information about lucrative markets-the report analyses the market across varied regions.
Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the humanized mouse and rat model market.
Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players such as Charles River Laboratories (US), The Jackson Laboratory (JAX) (US), Inotiv (US), and genOway (France).

Product Code: BT 4938

1 INTRODUCTION

1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 INCLUSIONS AND EXCLUSIONS
1.4 STUDY SCOPE
- 1.4.1 MARKET SEGMENTATION AND REGIONS COVERED
- 1.4.2 YEARS CONSIDERED
- 1.4.3 CURRENCY CONSIDERED
1.5 STAKEHOLDERS
1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

2.1 RESEARCH DATA
- 2.1.1 SECONDARY DATA
  - 2.1.1.1 Objectives of secondary research
- 2.1.2 PRIMARY DATA
  - 2.1.2.1 Objectives of primary research
2.2 MARKET SIZE ESTIMATION
- 2.2.1 GLOBAL MARKET ESTIMATION
- 2.2.2 SEGMENTAL MARKET ESTIMATION
2.3 GROWTH RATE PROJECTIONS
2.4 DATA TRIANGULATION
2.5 RESEARCH ASSUMPTIONS
2.6 RESEARCH LIMITATIONS
2.7 RISK ANALYSIS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 HUMANIZED MOUSE AND RAT MODEL MARKET OVERVIEW
4.2 NORTH AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER AND COUNTRY, 2024
4.3 HUMANIZED MOUSE AND RAT MODEL MARKET, BY KEY COUNTRY
4.4 HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER

5 MARKET OVERVIEW

5.1 INTRODUCTION
5.2 MARKET DYNAMICS
- 5.2.1 DRIVERS
  - 5.2.1.1 Rising use of humanized models in drug discovery research
  - 5.2.1.2 Emerging preclinical applications of humanized mouse models
  - 5.2.1.3 Government-funded initiatives for cancer research
  - 5.2.1.4 Increasing R&D activities in pharmaceutical & biotechnology industry
- 5.2.2 RESTRAINTS
  - 5.2.2.1 Introduction of FDA Modernization Act 2.0/3.0
  - 5.2.2.2 Stringent regulatory compliance for ethical use of animal models
- 5.2.3 OPPORTUNITIES
  - 5.2.3.1 Growing preference for humanized PDX models
  - 5.2.3.2 Emergence of CRISPR in biomedical research
- 5.2.4 CHALLENGES
  - 5.2.4.1 Alternative methods for animal testing
  - 5.2.4.2 Limitations of humanized mouse models
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
5.4 PRICING ANALYSIS
- 5.4.1 AVERAGE SELLING PRICE TREND OF PRODUCTS, BY KEY PLAYER, 2022-2024
- 5.4.2 AVERAGE SELLING PRICE TREND OF KEY PRODUCTS, BY REGION
5.5 SUPPLY CHAIN ANALYSIS
5.6 VALUE CHAIN ANALYSIS
5.7 ECOSYSTEM ANALYSIS
5.8 INVESTMENT AND FUNDING SCENARIO
5.9 TECHNOLOGY ANALYSIS
- 5.9.1 KEY TECHNOLOGIES
  - 5.9.1.1 CRISPR-Cas9
  - 5.9.1.2 Tissue engineering
  - 5.9.1.3 In vivo imaging
- 5.9.2 COMPLEMENTARY TECHNOLOGIES
  - 5.9.2.1 3D cell culture
  - 5.9.2.2 Organs-on-Chips
  - 5.9.2.3 Biomarker discovery
- 5.9.3 ADJACENT TECHNOLOGIES
  - 5.9.3.1 Proteomics
  - 5.9.3.2 Microfluidics
  - 5.9.3.3 Regenerative medicine
5.10 PATENT ANALYSIS
5.11 TRADE ANALYSIS
5.12 KEY CONFERENCES AND EVENTS, 2025-2026
5.13 REGULATORY LANDSCAPE
- 5.13.1 REGULATORY FRAMEWORK
- 5.13.2 NORTH AMERICA
- 5.13.3 EUROPE
- 5.13.4 ASIA PACIFIC
  - 5.13.4.1 China
  - 5.13.4.2 Japan
  - 5.13.4.3 India
  - 5.13.4.4 Australia
- 5.13.5 LATIN AMERICA
- 5.13.6 MIDDLE EAST & AFRICA
- 5.13.7 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.14 PORTER'S FIVE FORCES ANALYSIS
- 5.14.1 THREAT OF NEW ENTRANTS
- 5.14.2 THREAT OF SUBSTITUTES
- 5.14.3 BARGAINING POWER OF SUPPLIERS
- 5.14.4 BARGAINING POWER OF BUYERS
- 5.14.5 INTENSITY OF COMPETITIVE RIVALRY
5.15 KEY STAKEHOLDERS AND BUYING CRITERIA
- 5.15.1 KEY STAKEHOLDERS IN BUYING PROCESS
- 5.15.2 KEY BUYING CRITERIA, BY END USER
5.16 IMPACT OF AI ON HUMANIZED MOUSE AND RAT MODEL MARKET
- 5.16.1 INTRODUCTION
- 5.16.2 MARKET POTENTIAL OF AI IN HUMANIZED MOUSE AND RAT MODELS
- 5.16.3 AI USE CASES
- 5.16.4 KEY COMPANIES IMPLEMENTING AI
- 5.16.5 FUTURE OF GENERATIVE AI IN HUMANIZED MOUSE AND RAT MODEL MARKET

6 HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE

6.1 INTRODUCTION
6.2 HUMANIZED MOUSE MODELS
- 6.2.1 GENETIC HUMANIZED MOUSE MODELS
  - 6.2.1.1 Advancements in genetical engineering technologies to drive market
- 6.2.2 CELL-BASED HUMANIZED MOUSE MODELS
  - 6.2.2.1 CD34 humanized mouse models
    - 6.2.2.1.1 Rising demand for stem cell therapy to propel market
  - 6.2.2.2 PBMC humanized mouse models
    - 6.2.2.2.1 Growing prevalence of infectious diseases to boost demand
  - 6.2.2.3 BLT humanized mouse models
    - 6.2.2.3.1 Surge in HIV cases to drive market
6.3 HUMANIZED RAT MODELS
- 6.3.1 PREFERENCE FOR SRG RAT MODELS FOR RESEARCH STUDIES WITH LARGE SAMPLE SIZE SUPPORTS THE SEGMENT GROWTH

7 HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER

7.1 INTRODUCTION
7.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
- 7.2.1 GROWING ADOPTION OF HU-MICE MODELS IN VACCINE DEVELOPMENT TO BOOST SEGMENT GROWTH
7.3 CONTRACT RESEARCH ORGANIZATIONS AND CONTRACT DEVELOPMENT MANUFACTURING ORGANIZATIONS
- 7.3.1 OUTSOURCING OF DRUG DISCOVERY SERVICES BY PHARMA & BIOTECH COMPANIES TO PROPEL MARKET
7.4 ACADEMIC & RESEARCH INSTITUTES
- 7.4.1 SUPPORTIVE FUNDING INVESTMENTS FOR LIFE SCIENCE RESEARCH TO DRIVE MARKET

8 HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION

8.1 INTRODUCTION
8.2 ONCOLOGY
- 8.2.1 UTILIZATION OF MOUSE MODELS IN CANCER RESEARCH TO DRIVE MARKET
8.3 IMMUNOLOGY AND INFECTIOUS DISEASES
- 8.3.1 DEVELOPMENT OF ADVANCED MODELS FOR TREATMENT OF RARE DISEASES TO DRIVE MARKET
8.4 NEUROSCIENCE
- 8.4.1 RISING INCIDENCE OF CNS DISORDERS TO DRIVE MARKET
8.5 TOXICOLOGY
- 8.5.1 INCREASING CLINICAL TRIALS FOR TOXICOLOGY STUDIES TO SUPPORT MARKET GROWTH
8.6 HEMATOPOIESIS
- 8.6.1 RISING DEMAND FOR STEM CELL THERAPY TO DRIVE MARKET
8.7 OTHER APPLICATIONS

9 HUMANIZED MOUSE AND RAT MODEL MARKET, BY REGION

9.1 INTRODUCTION
9.2 NORTH AMERICA
- 9.2.1 MACROECONOMIC OUTLOOK OF NORTH AMERICA
- 9.2.2 US
  - 9.2.2.1 Growing research initiatives on mAbs and biosimilars to drive market
- 9.2.3 CANADA
  - 9.2.3.1 Government initiatives on stem cell research to drive market
9.3 EUROPE
- 9.3.1 MACROECONOMIC OUTLOOK OF EUROPE
- 9.3.2 GERMANY
  - 9.3.2.1 Rising pharmaceutical R&D expenditure to drive market
- 9.3.3 UK
  - 9.3.3.1 Growing investments in cancer research to drive market
- 9.3.4 FRANCE
  - 9.3.4.1 Rising initiatives for genomics research to support market growth
- 9.3.5 ITALY
  - 9.3.5.1 Robust pharmaceutical production to fuel market
- 9.3.6 SPAIN
  - 9.3.6.1 Rising growth in biotech industry to drive market
- 9.3.7 REST OF EUROPE
9.4 ASIA PACIFIC
- 9.4.1 MACROECONOMIC OUTLOOK OF ASIA PACIFIC
- 9.4.2 CHINA
  - 9.4.2.1 High growth in pharmaceutical industry to drive market
- 9.4.3 JAPAN
  - 9.4.3.1 Growing research collaborations among pharmaceutical companies to drive market
- 9.4.4 INDIA
  - 9.4.4.1 Growth in biotech industry to drive market
- 9.4.5 SOUTH KOREA
  - 9.4.5.1 Rising government-funded investments for pharmaceutical R&D to drive market
- 9.4.6 AUSTRALIA
  - 9.4.6.1 Rising biomedical research projects to drive market
- 9.4.7 REST OF ASIA PACIFIC
9.5 LATIN AMERICA
- 9.5.1 GROWING PRESENCE OF PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES TO PROPEL MARKET
- 9.5.2 MACROECONOMIC OUTLOOK OF LATIN AMERICA
9.6 MIDDLE EAST
- 9.6.1 GROWING PHARMACEUTICAL MARKET IN COUNTRIES TO SUPPORT MARKET GROWTH
- 9.6.2 MACROECONOMIC OUTLOOK FOR MIDDLE EAST
9.7 AFRICA
- 9.7.1 GROWING PHARMACEUTICAL INDUSTRY TO SUPPORT MARKET GROWTH
- 9.7.2 MACROECONOMIC OUTLOOK FOR AFRICA

10 COMPETITIVE LANDSCAPE

10.1 INTRODUCTION
10.2 KEY PLAYER STRATEGY/RIGHT TO WIN
- 10.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN HUMANIZED MOUSE AND RAT MODEL MARKET
10.3 REVENUE ANALYSIS, 2020-2024
10.4 MARKET SHARE ANALYSIS, 2024
- 10.4.1 HUMANIZED MOUSE AND RAT MODEL MARKET
10.5 COMPANY VALUATION AND FINANCIAL METRICS
- 10.5.1 FINANCIAL METRICS
10.6 BRAND/PRODUCT COMPARISON
10.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
- 10.7.1 STARS
- 10.7.2 EMERGING LEADERS
- 10.7.3 PERVASIVE PLAYERS
- 10.7.4 PARTICIPANTS
- 10.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
  - 10.7.5.1 Company footprint
  - 10.7.5.2 Region footprint
  - 10.7.5.3 Type footprint
  - 10.7.5.4 Application footprint
10.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
- 10.8.1 PROGRESSIVE COMPANIES
- 10.8.2 RESPONSIVE COMPANIES
- 10.8.3 DYNAMIC COMPANIES
- 10.8.4 STARTING BLOCKS
- 10.8.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES
  - 10.8.5.1 Detailed list of key startups/SMEs
  - 10.8.5.2 Competitive benchmarking of key startups/SMEs
10.9 COMPETITIVE SCENARIO
- 10.9.1 PRODUCT LAUNCHES & APPROVALS
- 10.9.2 DEALS
- 10.9.3 EXPANSIONS

11 COMPANY PROFILES

11.1 KEY PLAYERS
- 11.1.1 CHARLES RIVER LABORATORIES
  - 11.1.1.1 Business overview
  - 11.1.1.2 Products offered
  - 11.1.1.3 Recent developments
    - 11.1.1.3.1 Deals
    - 11.1.1.3.2 Other developments
  - 11.1.1.4 MnM view
    - 11.1.1.4.1 Key strengths
    - 11.1.1.4.2 Strategic choices
    - 11.1.1.4.3 Weaknesses and competitive threats
- 11.1.2 THE JACKSON LABORATORY
  - 11.1.2.1 Business overview
  - 11.1.2.2 Products offered
  - 11.1.2.3 Recent developments
    - 11.1.2.3.1 Deals
  - 11.1.2.4 MnM view
    - 11.1.2.4.1 Key strengths
    - 11.1.2.4.2 Strategic choices
    - 11.1.2.4.3 Weaknesses and competitive threats
- 11.1.3 INOTIV
  - 11.1.3.1 Business overview
  - 11.1.3.2 Products offered
  - 11.1.3.3 Recent developments
    - 11.1.3.3.1 Deals
  - 11.1.3.4 MnM view
    - 11.1.3.4.1 Key strengths
    - 11.1.3.4.2 Strategic choices
    - 11.1.3.4.3 Weaknesses and competitive threats
- 11.1.4 GENOWAY
  - 11.1.4.1 Business overview
  - 11.1.4.2 Products offered
  - 11.1.4.3 Recent developments
    - 11.1.4.3.1 Other developments
  - 11.1.4.4 MnM view
    - 11.1.4.4.1 Key strengths
    - 11.1.4.4.2 Strategic choices
    - 11.1.4.4.3 Weaknesses and competitive threats
- 11.1.5 TACONIC BIOSCIENCES, INC.
  - 11.1.5.1 Business overview
  - 11.1.5.2 Products offered
  - 11.1.5.3 Recent developments
    - 11.1.5.3.1 Product launches
    - 11.1.5.3.2 Expansions
- 11.1.6 JSR CORPORATION
  - 11.1.6.1 Business overview
  - 11.1.6.2 Products offered
  - 11.1.6.3 Recent developments
    - 11.1.6.3.1 Deals
    - 11.1.6.3.2 Expansions
- 11.1.7 CHAMPIONS ONCOLOGY, INC.
  - 11.1.7.1 Business overview
  - 11.1.7.2 Products offered
- 11.1.8 JANVIER LABS
  - 11.1.8.1 Business overview
  - 11.1.8.2 Products offered
  - 11.1.8.3 Recent developments
    - 11.1.8.3.1 Deals
- 11.1.9 VITALSTAR BIOTECHNOLOGY
  - 11.1.9.1 Business overview
  - 11.1.9.2 Products offered
- 11.1.10 INGENIOUS TARGETING LABORATORY
  - 11.1.10.1 Business overview
  - 11.1.10.2 Products offered
- 11.1.11 HARBOUR BIOMED
  - 11.1.11.1 Business overview
  - 11.1.11.2 Products offered
  - 11.1.11.3 Recent developments
    - 11.1.11.3.1 Deals
- 11.1.12 ONCODESIGN SERVICES
  - 11.1.12.1 Business overview
  - 11.1.12.2 Products offered
- 11.1.13 PHARMATEST SERVICES
  - 11.1.13.1 Business overview
  - 11.1.13.2 Products offered
11.2 OTHER PLAYERS
- 11.2.1 OZGENE PTY LTD.
- 11.2.2 CLEA JAPAN, INC.
- 11.2.3 ALTOGEN LABS
- 11.2.4 REACTION BIOLOGY
- 11.2.5 TRANSCURE BIOSERVICES
- 11.2.6 CYAGEN
- 11.2.7 ARAGEN LIFE SCIENCES LTD.
- 11.2.8 BIOCYTOGEN
- 11.2.9 GEMPHARMATECH

12 APPENDIX

12.1 DISCUSSION GUIDE
12.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
12.3 CUSTOMIZATION OPTIONS
12.4 RELATED REPORTS
12.5 AUTHOR DETAILS

Product Code: BT 4938

List of Tables

TABLE 1 HUMANIZED MOUSE AND RAT MODEL MARKET: INCLUSIONS AND EXCLUSIONS
TABLE 2 IMPACT ANALYSIS OF SUPPLY AND DEMAND-SIDE FACTORS
TABLE 3 HUMANIZED MOUSE AND RAT MODEL MARKET: RISK ANALYSIS
TABLE 4 HUMANIZED MOUSE AND RAT MODEL MARKET: IMPACT ANALYSIS OF MARKET DYNAMICS
TABLE 5 NUMBER OF R&D PRODUCTS, BY INDICATION (2024)
TABLE 6 AVERAGE SELLING PRICE TREND OF PRODUCTS, BY KEY PLAYER, 2022-2024 (USD MILLION)
TABLE 7 AVERAGE SELLING PRICE TREND OF KEY PRODUCTS, BY REGION, 2022-2024 (USD)
TABLE 8 AVERAGE SELLING PRICE TREND OF KEY PRODUCTS (HUMANIZED MOUSE MODELS), BY REGION, 2022-2024 (USD)
TABLE 9 HUMANIZED MOUSE AND RAT MODEL MARKET: ROLE OF COMPANIES IN ECOSYSTEM
TABLE 10 INVESTMENT AND FUNDING ACTIVITY, BY KEY PLAYER, 2021-2025
TABLE 11 HUMANIZED MOUSE AND RAT MODEL MARKET: INNOVATIONS AND PATENT REGISTRATIONS, 2021-2024
TABLE 12 IMPORT DATA FOR LABORATORY MOUSE
TABLE 13 EXPORT DATA FOR LABORATORY MOUSE
TABLE 14 HUMANIZED MOUSE AND RAT MODEL MARKET: KEY CONFERENCES AND EVENTS, 2025-2026
TABLE 15 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 16 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 17 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 18 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 19 HUMANIZED MOUSE AND RAT MODEL MARKET: PORTER'S FIVE FORCES ANALYSIS
TABLE 20 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS (%)
TABLE 21 KEY BUYING CRITERIA, BY END USER
TABLE 22 HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 23 HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2023-2030 (THOUSAND UNITS)
TABLE 24 HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 25 HUMANIZED MOUSE MODELS MARKET, BY REGION, 2023-2030 (USD MILLION)
TABLE 26 NORTH AMERICA: HUMANIZED MOUSE MODELS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 27 EUROPE: HUMANIZED MOUSE MODELS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 28 ASIA PACIFIC: HUMANIZED MOUSE MODELS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 29 GENETIC HUMANIZED MOUSE MODELS MARKET, BY REGION, 2023-2030 (USD MILLION)
TABLE 30 NORTH AMERICA: GENETIC HUMANIZED MOUSE MODELS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 31 EUROPE: GENETIC HUMANIZED MOUSE MODELS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 32 ASIA PACIFIC: GENETIC HUMANIZED MOUSE MODELS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 33 CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 34 CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY REGION, 2023-2030 (USD MILLION)
TABLE 35 NORTH AMERICA: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 36 EUROPE: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 37 ASIA PACIFIC: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 38 CD34 HUMANIZED MODELS MARKET, BY REGION, 2023-2030 (USD MILLION)
TABLE 39 NORTH AMERICA: CD34 HUMANIZED MODELS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 40 EUROPE: CD34 HUMANIZED MODELS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 41 ASIA PACIFIC: CD34 HUMANIZED MODELS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 42 PBMC HUMANIZED MICE MODELS MARKET, BY REGION, 2023-2030 (USD MILLION)
TABLE 43 NORTH AMERICA: PBMC HUMANIZED MICE MODELS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 44 EUROPE: PBMC HUMANIZED MICE MODELS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 45 ASIA PACIFIC: PBMC HUMANIZED MICE MODELS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 46 BLT HUMANIZED MOUSE MODELS MARKET, BY REGION, 2023-2030 (USD MILLION)
TABLE 47 NORTH AMERICA: BLT HUMANIZED MOUSE MODELS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 48 EUROPE: BLT HUMANIZED MOUSE MODELS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 49 ASIA PACIFIC: BLT HUMANIZED MOUSE MODELS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 50 HUMANIZED RAT MODELS MARKET, BY REGION, 2023-2030 (USD MILLION)
TABLE 51 NORTH AMERICA: HUMANIZED RAT MODELS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 52 EUROPE: HUMANIZED RAT MODELS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 53 ASIA PACIFIC: HUMANIZED RAT MODELS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 54 HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2023-2030 (USD MILLION)
TABLE 55 USE OF HUMANIZED MICE MODELS IN DEVELOPED AND TESTED VACCINES
TABLE 56 HUMANIZED MOUSE AND RAT MODEL MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023-2030 (USD MILLION)
TABLE 57 NORTH AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 58 EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 59 ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 60 HUMANIZED MOUSE AND RAT MODEL MARKET FOR CROS AND CDMOS, BY REGION, 2023-2030 (USD MILLION)
TABLE 61 NORTH AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET FOR CROS AND CDMOS, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 62 EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET FOR CROS AND CDMOS, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 63 ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET FOR CROS AND CDMOS, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 64 HUMANIZED MOUSE AND RAT MODEL MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2023-2030 (USD MILLION)
TABLE 65 NORTH AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 66 EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 67 ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 68 HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
TABLE 69 HUMANIZED MOUSE AND RAT MODEL MARKET FOR ONCOLOGY, BY REGION, 2023-2030 (USD MILLION)
TABLE 70 NORTH AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET FOR ONCOLOGY, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 71 EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET FOR ONCOLOGY, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 72 ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET FOR ONCOLOGY, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 73 HUMANIZED MOUSE AND RAT MODEL MARKET FOR IMMUNOLOGY AND INFECTIOUS DISEASES, BY REGION, 2023-2030 (USD MILLION)
TABLE 74 NORTH AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET FOR IMMUNOLOGY AND INFECTIOUS DISEASES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 75 EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET FOR IMMUNOLOGY AND INFECTIOUS DISEASES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 76 ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET FOR IMMUNOLOGY AND INFECTIOUS DISEASES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 77 HUMANIZED MOUSE AND RAT MODEL MARKET FOR NEUROSCIENCE, BY REGION, 2023-2030 (USD MILLION)
TABLE 78 NORTH AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET FOR NEUROSCIENCE, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 79 EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET FOR NEUROSCIENCE, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 80 ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET FOR NEUROSCIENCE, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 81 HUMANIZED MOUSE AND RAT MODEL MARKET FOR TOXICOLOGY, BY REGION, 2023-2030 (USD MILLION)
TABLE 82 NORTH AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET FOR TOXICOLOGY, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 83 EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET FOR TOXICOLOGY, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 84 ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET FOR TOXICOLOGY, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 85 HUMANIZED MOUSE AND RAT MODEL MARKET FOR HEMATOPOIESIS, BY REGION, 2023-2030 (USD MILLION)
TABLE 86 NORTH AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET FOR HEMATOPOIESIS, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 87 EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET FOR HEMATOPOIESIS, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 88 ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET FOR HEMATOPOIESIS, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 89 HUMANIZED MOUSE AND RAT MODEL MARKET FOR OTHER APPLICATIONS, BY REGION, 2023-2030 (USD MILLION)
TABLE 90 NORTH AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 91 EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 92 ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 93 HUMANIZED MOUSE AND RAT MODEL MARKET, BY REGION, 2023-2030 (USD MILLION)
TABLE 94 NORTH AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 95 NORTH AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 96 NORTH AMERICA: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 97 NORTH AMERICA: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 98 NORTH AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
TABLE 99 NORTH AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2023-2030 (USD MILLION)
TABLE 100 KEY MACROECONOMIC INDICATORS OF NORTH AMERICA
TABLE 101 US: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 102 US: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 103 US: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 104 US: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
TABLE 105 US: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2023-2030 (USD MILLION)
TABLE 106 CANADA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 107 CANADA: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 108 CANADA: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 109 CANADA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
TABLE 110 CANADA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2023-2030 (USD MILLION)
TABLE 111 EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 112 EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 113 EUROPE: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 114 EUROPE: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 115 EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
TABLE 116 EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2023-2030 (USD MILLION)
TABLE 117 KEY MACROECONOMIC INDICATORS OF EUROPE
TABLE 118 GERMANY: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 119 GERMANY: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 120 GERMANY: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 121 GERMANY: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
TABLE 122 GERMANY: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2023-2030 (USD MILLION)
TABLE 123 UK: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 124 UK: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 125 UK: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 126 UK: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
TABLE 127 UK: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2023-2030 (USD MILLION)
TABLE 128 FRANCE: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 129 FRANCE: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 130 FRANCE: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 131 FRANCE: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
TABLE 132 FRANCE: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2023-2030 (USD MILLION)
TABLE 133 ITALY: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 134 ITALY: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 135 ITALY: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 136 ITALY: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
TABLE 137 ITALY: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2023-2030 (USD MILLION)
TABLE 138 SPAIN: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 139 SPAIN: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 140 SPAIN: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 141 SPAIN: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
TABLE 142 SPAIN: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2023-2030 (USD MILLION)
TABLE 143 REST OF EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 144 REST OF EUROPE: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 145 REST OF EUROPE: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 146 REST OF EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
TABLE 147 REST OF EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2023-2030 (USD MILLION)
TABLE 148 ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 149 ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 150 ASIA PACIFIC: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 151 ASIA PACIFIC: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 152 ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
TABLE 153 ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2023-2030 (USD MILLION)
TABLE 154 KEY MACROECONOMIC INDICATORS OF ASIA PACIFIC
TABLE 155 CHINA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 156 CHINA: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 157 CHINA: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 158 CHINA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
TABLE 159 CHINA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2023-2030 (USD MILLION)
TABLE 160 JAPAN: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 161 JAPAN: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 162 JAPAN: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 163 JAPAN: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
TABLE 164 JAPAN: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2023-2030 (USD MILLION)
TABLE 165 INDIA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 166 INDIA: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 167 INDIA: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 168 INDIA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
TABLE 169 INDIA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2023-2030 (USD MILLION)
TABLE 170 SOUTH KOREA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 171 SOUTH KOREA: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 172 SOUTH KOREA: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 173 SOUTH KOREA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
TABLE 174 SOUTH KOREA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2023-2030 (USD MILLION)
TABLE 175 AUSTRALIA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 176 AUSTRALIA: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 177 AUSTRALIA: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 178 AUSTRALIA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
TABLE 179 AUSTRALIA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2023-2030 (USD MILLION)
TABLE 180 REST OF ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 181 REST OF ASIA PACIFIC: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 182 REST OF ASIA PACIFIC: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 183 REST OF ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
TABLE 184 REST OF ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2023-2030 (USD MILLION)
TABLE 185 LATIN AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 186 LATIN AMERICA: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 187 LATIN AMERICA: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 188 LATIN AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
TABLE 189 LATIN AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2023-2030 (USD MILLION)
TABLE 190 KEY MACROECONOMIC INDICATORS OF LATIN AMERICA
TABLE 191 MIDDLE EAST: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 192 MIDDLE EAST: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 193 MIDDLE EAST: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 194 MIDDLE EAST: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
TABLE 195 MIDDLE EAST: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2023-2030 (USD MILLION)
TABLE 196 KEY MACROECONOMIC INDICATORS OF MIDDLE EAST
TABLE 197 AFRICA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 198 AFRICA: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 199 AFRICA: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 200 AFRICA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
TABLE 201 AFRICA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2023-2030 (USD MILLION)
TABLE 202 KEY MACROECONOMIC INDICATORS OF AFRICA
TABLE 203 STRATEGIES ADOPTED BY KEY PLAYERS IN HUMANIZED MOUSE AND RAT MODEL MARKET, 2021-2024
TABLE 204 HUMANIZED MOUSE AND RAT MODEL MARKET: DEGREE OF COMPETITION
TABLE 205 HUMANIZED MOUSE AND RAT MODEL MARKET: REGION FOOTPRINT
TABLE 206 HUMANIZED MOUSE AND RAT MODEL MARKET: TYPE FOOTPRINT
TABLE 207 HUMANIZED MOUSE AND RAT MODEL MARKET: APPLICATION FOOTPRINT
TABLE 208 HUMANIZED MOUSE AND RAT MODEL MARKET: KEY STARTUPS/SMES
TABLE 209 HUMANIZED MOUSE AND RAT MODEL MARKET: COMPETITIVE BENCHMARKING OF KEY START UPS/SMES
TABLE 210 HUMANIZED MOUSE AND RAT MODEL MARKET: PRODUCT LAUNCHES, JANUARY 2021-MARCH 2025
TABLE 211 HUMANIZED MOUSE AND RAT MODEL MARKET: DEALS, JANUARY 2021-MARCH 2025
TABLE 212 HUMANIZED MOUSE AND RAT MODEL MARKET: EXPANSIONS, JANUARY 2021-MARCH 2025
TABLE 213 CHARLES RIVER LABORATORIES: COMPANY OVERVIEW
TABLE 214 CHARLES RIVER LABORATORIES: PRODUCTS OFFERED
TABLE 215 CHARLES RIVER LABORATORIES: DEALS, JANUARY 2021-JANUARY 2025
TABLE 216 CHARLES RIVER LABORATORIES: OTHER DEVELOPMENTS, JANUARY 2021-JANUARY 2025
TABLE 217 THE JACKSON LABORATORY: COMPANY OVERVIEW
TABLE 218 THE JACKSON LABORATORY: PRODUCTS OFFERED
TABLE 219 THE JACKSON LABORATORY: DEALS, JANUARY 2021-JANUARY 2025
TABLE 220 INOTIV: COMPANY OVERVIEW
TABLE 221 INOTIV: PRODUCTS OFFERED
TABLE 222 INOTIV: DEALS, JANUARY 2021-JANUARY 2025
TABLE 223 GENOWAY: COMPANY OVERVIEW
TABLE 224 GENOWAY: PRODUCTS OFFERED
TABLE 225 GENOWAY: OTHER DEVELOPMENTS, JANUARY 2021-JANUARY 2025
TABLE 226 TACONIC BIOSCIENCES, INC.: COMPANY OVERVIEW
TABLE 227 TACONIC BIOSCIENCES, INC.: PRODUCTS OFFERED
TABLE 228 TACONIC BIOSCIENCES, INC.: PRODUCT LAUNCHES, JANUARY 2021-JANUARY 2025
TABLE 229 TACONIC BIOSCIENCES, INC.: EXPANSIONS, JANUARY 2021-JANUARY 2025
TABLE 230 JSR CORPORATION: COMPANY OVERVIEW
TABLE 231 JSR CORPORATION: PRODUCTS OFFERED
TABLE 232 JSR CORPORATION: DEALS, JANUARY 2021-JANUARY 2025
TABLE 233 JSR CORPORATION: EXPANSIONS, JANUARY 2021-JANUARY 2025
TABLE 234 CHAMPIONS ONCOLOGY, INC.: COMPANY OVERVIEW
TABLE 235 CHAMPIONS ONCOLOGY, INC.: PRODUCTS OFFERED
TABLE 236 JANVIER LABS: COMPANY OVERVIEW
TABLE 237 JANVIER LABS: PRODUCTS OFFERED
TABLE 238 JANVIER LABS: DEALS, JANUARY 2021-JANUARY 2025
TABLE 239 VITALSTAR BIOTECHNOLOGY: COMPANY OVERVIEW
TABLE 240 VITALSTAR BIOTECHNOLOGY: PRODUCTS OFFERED
TABLE 241 INGENIOUS TARGETING LABORATORY: COMPANY OVERVIEW
TABLE 242 INGENIOUS TARGETING LABORATORY: PRODUCTS OFFERED
TABLE 243 HARBOUR BIOMED: COMPANY OVERVIEW
TABLE 244 HARBOUR BIOMED: PRODUCTS OFFERED
TABLE 245 HARBOUR BIOMED: DEALS, JANUARY 2021-JANUARY 2025
TABLE 246 ONCODESIGN SERVICES: COMPANY OVERVIEW
TABLE 247 ONCODESIGN SERVICES: PRODUCTS OFFERED
TABLE 248 PHARMATEST SERVICES: COMPANY OVERVIEW
TABLE 249 PHARMATEST SERVICES: PRODUCTS OFFERED
TABLE 250 OZGENE PTY LTD.: COMPANY OVERVIEW
TABLE 251 CLEA JAPAN, INC.: COMPANY OVERVIEW
TABLE 252 ALTOGEN LABS: COMPANY OVERVIEW
TABLE 253 REACTION BIOLOGY: COMPANY OVERVIEW
TABLE 254 TRANSCURE BIOSERVICES: COMPANY OVERVIEW
TABLE 255 CYAGEN: COMPANY OVERVIEW
TABLE 256 ARAGEN LIFE SCIENCES LTD.: COMPANY OVERVIEW
TABLE 257 BIOCYTOGEN: COMPANY OVERVIEW
TABLE 258 GEMPHARMATECH: COMPANY OVERVIEW

List of Figures

FIGURE 1 HUMANIZED MOUSE AND RAT MODEL MARKET SEGMENTATION AND REGIONS CONSIDERED
FIGURE 2 HUMANIZED MOUSE AND RAT MODEL MARKET: YEARS CONSIDERED
FIGURE 3 HUMANIZED MOUSE AND RAT MODEL MARKET: RESEARCH DESIGN
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY RESPONDENT, DESIGNATION, AND REGION
FIGURE 5 GLOBAL HUMANIZED MOUSE AND RAT MODEL MARKET SIZE ESTIMATION, 2024
FIGURE 6 COMPANY REVENUE ANALYSIS-BASED ESTIMATION, 2024
FIGURE 7 REVENUE SHARE ANALYSIS: ILLUSTRATIVE EXAMPLE OF CHARLES RIVER LABORATORIES, 2024
FIGURE 8 MARKET SIZE VALIDATION FROM PRIMARIES
FIGURE 9 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
FIGURE 10 HUMANIZED MOUSE AND RAT MODEL MARKET: CAGR PROJECTIONS, 2025-2030
FIGURE 11 HUMANIZED MOUSE AND RAT MODEL MARKET: DATA TRIANGULATION
FIGURE 12 HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2025 VS. 2030 (USD MILLION)
FIGURE 13 HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2025 VS. 2030 (USD MILLION)
FIGURE 14 HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2025 VS. 2030 (USD MILLION)
FIGURE 15 REGIONAL SNAPSHOT OF HUMANIZED MOUSE AND RAT MODEL MARKET, 2025-2030
FIGURE 16 RISING USE OF HUMANIZED MODELS IN DRUG DISCOVERY RESEARCH TO DRIVE MARKET
FIGURE 17 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN US IN 2024
FIGURE 18 CHINA TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD
FIGURE 19 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES SEGMENT DOMINATED MARKET IN 2024
FIGURE 20 HUMANIZED MOUSE AND RAT MODEL MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 21 NUMBER OF CLINICAL TRIALS REGISTERED FOR CANCER IMMUNOTHERAPIES, 2020-2024
FIGURE 22 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
FIGURE 23 AVERAGE SELLING PRICE TREND OF PRODUCTS, BY KEY PLAYER, 2022-2024 (USD)
FIGURE 24 AVERAGE SELLING PRICE TREND OF KEY PRODUCTS, BY REGION, 2022-2024 (USD)
FIGURE 25 AVERAGE SELLING PRICE TREND OF KEY PRODUCTS, BY REGION, 2022-2024 (USD)
FIGURE 26 HUMANIZED MOUSE AND RAT MODEL MARKET: SUPPLY CHAIN ANALYSIS
FIGURE 27 HUMANIZED MOUSE AND RAT MODEL MARKET: VALUE CHAIN ANALYSIS
FIGURE 28 HUMANIZED MOUSE AND RAT MODEL MARKET ECOSYSTEM
FIGURE 29 INVESTMENT AND FUNDING SCENARIO, 2021-2025
FIGURE 30 HUMANIZED MOUSE AND RAT MODEL MARKET: PATENT ANALYSIS, 2014-2024
FIGURE 31 HUMANIZED MOUSE AND RAT MODEL MARKET: PORTER'S FIVE FORCES ANALYSIS
FIGURE 32 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS
FIGURE 33 KEY BUYING CRITERIA, BY END USER
FIGURE 34 AI USE CASES
FIGURE 35 HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2023-2030 (THOUSAND UNITS)
FIGURE 36 HUMANIZED MOUSE AND RAT MODEL MARKET: NORTH AMERICA SNAPSHOT
FIGURE 37 HUMANIZED MOUSE AND RAT MODEL MARKET: ASIA PACIFIC SNAPSHOT
FIGURE 38 REVENUE ANALYSIS OF KEY PLAYERS IN HUMANIZED MOUSE AND RAT MODEL MARKET, 2020-2024
FIGURE 39 MARKET SHARE ANALYSIS OF HUMANIZED MOUSE AND RAT MODEL MARKET, 2024
FIGURE 40 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS, 2024
FIGURE 41 COMPANY VALUATION AND FINANCIAL METRICS, 2024
FIGURE 42 HUMANIZED MOUSE AND RAT MODEL MARKET: BRAND/PRODUCT COMPARISON
FIGURE 43 HUMANIZED MOUSE AND RAT MODEL MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024
FIGURE 44 HUMANIZED MOUSE AND RAT MODEL MARKET: COMPANY FOOTPRINT
FIGURE 45 HUMANIZED MOUSE AND RAT MODEL MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024
FIGURE 46 CHARLES RIVER LABORATORIES: COMPANY SNAPSHOT (2024)
FIGURE 47 THE JACKSON LABORATORY: COMPANY SNAPSHOT (2024)
FIGURE 48 INOTIV: COMPANY SNAPSHOT (2024)
FIGURE 49 JSR CORPORATION: COMPANY SNAPSHOT (2024)
FIGURE 50 CHAMPIONS ONCOLOGY, INC.: COMPANY SNAPSHOT (2024)
FIGURE 51 HARBOUR BIOMED: COMPANY SNAPSHOT (2024)

Have a question?

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Christine Sirois

Manager - Americas

+1-860-674-8796

SEE OUR FAQ

Humanized Mouse and Rat Model Market by Type (Genetic Models, Cell-based Models, Rat Models), Application (Oncology, Immunology, Neuroscience, Toxicology, Infectious Diseases), End User (Pharma, Biotech), and Region - Global Forecast to 2030

Description

Table of Contents

List of Tables

The primary interviews conducted for this report can be categorized as follows:

Research Coverage:

Key Benefits of Buying the Report:

The report provides insights on the following pointers:

TABLE OF CONTENTS

1 INTRODUCTION

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

5 MARKET OVERVIEW

6 HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE

7 HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER

8 HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION

9 HUMANIZED MOUSE AND RAT MODEL MARKET, BY REGION

10 COMPETITIVE LANDSCAPE

11 COMPANY PROFILES

12 APPENDIX

List of Tables

List of Figures